Palmitoylethanolamide,
does it really help with Shorter sleep-onset latency and improved sleep quality and waking experience?
research showsIn a manufacturer-funded randomized trial, Levagen+® 350 mg for eight weeks showed signals for shorter time to fall asleep, shorter time to feel fully awake, and better cognition on waking. However, overall sleep quality and quantity were not better than placebo, and the latency result was confined to participants whose baseline latency exceeded ten minutes. Because this was a single branded-formulation trial that excluded people with diagnosed insomnia, the grade is C.
ads claimAdvertisements can broaden the finding to deep sleep, overall sleep-quality improvement, or resolution of insomnia. The direct evidence is a short trial of a specific Levagen+® dose, with signals for a latency subgroup and waking experience but null overall sleep quality and objective sleep quantity.
Useful facts when choosing a product
- Korean consumers can access both ordinary 300 mg PEA capsules and Levagen+® products using LipiSperse® through cross-border retail channels; these should not be treated as the same formulation.
- The pivotal sleep trial used Levagen+® 350 mg one hour before bedtime for eight weeks.
- The pain-associated trial used Levagen+® 600 mg/day and differed in dose, population, and primary purpose from the sleep trial.
- Short trials generally reported good tolerability, but data for long-term use, pregnancy and lactation, and severe illness are limited.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.palmitoylethanolamide.UNK.shorter-sleep-onset-latency-and-improved-sleep-quality-and-waking-experience.improve.placeboUnknown > Palmitoylethanolamide > Unknown > Shorter sleep-onset latency and improved sleep quality and waking experience > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The Rao 2021 trial randomized 125 adults with sleep complaints, of whom 103 completed the study. After eight weeks of Levagen+® 350 mg/day, sleep-onset latency among the subgroup with baseline latency over ten minutes and time to feel fully awake and cognition on waking improved, but the total Pittsburgh Sleep Quality Index score and actigraphy and diary measures of sleep time and quality did not differ from placebo. Diagnosed insomnia was excluded, and Gencor Pacific funded the study. In the Pickering 2022 trial of 70 patients with diabetic neuropathy, Levagen+® 600 mg/day improved Medical Outcomes Study sleep measures together with pain, but sleep was secondary and mediation by pain relief cannot be excluded.
Why this is classified as C (48)
A randomized branded-formulation trial is a strength, but overall sleep quality and quantity were null and the positive latency finding was subgroup-limited. Applying boundary rules ① and ②-b for a manufacturer-funded single product, exclusion of insomnia, and lack of independent replication gives C with 48 points.
Counterpoint. The evidence is not entirely null for latency and waking experience. The judgment is confined to the tested Levagen+® 350 mg regimen.
Rejudgment record. New verdict — Accepted latency and waking signals from one Levagen+® trial but applied rules ① and ②-b because overall sleep quality was null, the finding was subgroup-limited, insomnia was excluded, and funding was manufacturer-centered
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Sleep-onset latency, sleep quality, and waking experience in general adults | C | A single Levagen+® trial was positive for a latency subgroup and waking experience but null for overall Pittsburgh Sleep Quality Index and objective sleep quantity. |
| Clinical treatment of diagnosed insomnia | ? | The pivotal trial excluded people with insomnia, and no direct human efficacy trial in that population was identified. |
| Sleep disturbance accompanying pain | C | A neuropathic-pain trial improved a secondary sleep outcome, but the effect cannot be separated from pain reduction. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Rao A et al. 2021 | Double-blind randomized placebo-controlled trial | 125 randomized; 103 completed | Funded by Gencor Pacific, which supplied Levagen+® | Pittsburgh Sleep Quality Index, actigraphy, sleep diary, sleep-onset latency, and waking experience | Latency in the subgroup with baseline latency over ten minutes and waking experience improved, but overall sleep quality and quantity did not differ from placebo. | Key |
| Pickering E et al. 2022 | Single-center quadruple-blind randomized placebo-controlled trial | 70 patients with diabetic peripheral neuropathy | Gencor Pacific-funded branded formulation | Neuropathic pain as the primary outcome and the Medical Outcomes Study sleep scale as a secondary outcome | Pain and sleep measures improved together at 600 mg/day, so an independent sleep effect cannot be determined. | Supportive |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-18).
Final verification and publication gate: Codex · Evidence date: 2026-07-18 · Corrections: none
Cite this verdict
[Chamgap] Palmitoylethanolamide (PEA, Levagen+®) x sleep-onset latency, sleep quality, and waking experience — Evidence Grade C·48. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/palmitoylethanolamide-levagen-sleep/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.